Loading...
Please wait, while we are loading the content...
Similar Documents
The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
| Content Provider | MDPI |
|---|---|
| Author | Berckelaer, Christophe Van Vermeiren, Iris Vercauteren, Leonie Rypens, Charlotte Oner, Gizem Trinh, Xuan Bich Tjalma, Wiebren A. A. Broeckx, Glenn Charafe-Jauffret, Emmanuelle Laere, Steven Van Bertucci, François Colpaert, Cecile van Dam, Peter A. |
| Copyright Year | 2021 |
| Description | Introduction: Inflammatory breast cancer (IBC) is a rare but aggressive form of breast cancer (BC) in which the (prognostic) role of stromal tumour-infiltrating lymphocytes (sTIL) and the peripheral circulating immune cells in patients with residual disease (RD) after neo-adjuvant chemotherapy (NACT) is not clearly established. Methodology: To describe the evolution of sTIL and some peripheral inflammation markers (Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio and Lymphocyte-to-monocyte ratio) after NACT in IBC, we retrospectively collected clinicopathological variables for 125 stage III IBC patients. sTILs were scored by three different researchers on an H&E slide of the mastectomy specimen. A cohort of subtype-matched non-IBC breast cancer patients (nIBC) treated with NACT was included for comparison. Results: There was no significant difference in the pre- and posttreatment sTIL scores between IBC and nIBC and in both groups the number of sTIL was significantly lower after NACT. However, the IBC phenotype did correlate with a stronger decrease of sTIL after NACT (OR: 0.25, 95% CI: 0.073–0.76, p = 0.018). The change in the peripheral immune markers was not significantly different between IBC and nIBC. After NACT, 75 patients had residual disease. In this group, a high number of sTIL before NACT (HR: 0.23, 95% CI: 0.05–1.02, p = 0.05) was prognostic for a longer OS, while a low number of sTIL after NACT (HR: 0.33, 95% CI: 0.11–0.98, p = 0.046) and a low residual cancer cellularity (HR: 0.20, 95% CI: 0.08–0.52, p < 0.001) was associated with a longer DFS. Conclusions: IBC is associated with a significantly stronger decrease of sTIL after NACT compared to nIBC. Furthermore, a high number of sTIL after NACT was associated with a worse prognosis in IBC. |
| Starting Page | 4656 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers13184656 |
| Journal | Cancers |
| Issue Number | 18 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-09-16 |
| Access Restriction | Open |
| Subject Keyword | Cancers Oncology Inflammatory Breast Cancer (ibc) Neo-adjuvant Chemotherapy (nact) Stromal Tumour-infiltrating Lymphocytes (stil) Immune Response Lymphocyte-to-monocyte Ratio (lmr) Neutrophil-to-lymphocyte Ratio (nlr) Platelet-to-lymphocyte Ratio (plr) |
| Content Type | Text |
| Resource Type | Article |
